Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by New York Medical College.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Karen Seiter, New York Medical College Identifier:
First received: January 11, 2012
Last updated: January 19, 2012
Last verified: January 2012
CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of the regimen in patients with relapsed ALL.

Condition Intervention Phase
Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma
Burkitts Leukemia/Lymphoma
Chronic Myelogenous Leukemia
Drug: CLAG-M
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of CLAG-M in Relapsed ALL

Resource links provided by NLM:

Further study details as provided by New York Medical College:

Primary Outcome Measures:
  • Complete remission percentage [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: January 2012
Estimated Study Completion Date: January 2014
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CLAG-M Drug: CLAG-M
IV times 5 days
Other Names:
  • Leustatin
  • Ara-C
  • Novantrone
Drug: CLAG-M
Other Names:
  • Cladribine (Leustatin)
  • Cytarabine (Ara-c)
  • Mitoxantrone (Novantrone)

Detailed Description:
Patients will receive standard dose CLAG-M (cladribine, cytarabine, mitoxantrone, filgrastim). Standard support care will be given. Efficacy will be assessed through bone marrow examinations and blood tests.

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Relapsed or refractory acute lymphoblastic leukemia,
  • Burkitts leukemia/lymphoma,
  • Lymphoid blastic CML,
  • Lymphoblastic lymphoma.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01513603

Contact: Karen Seiter, MD 914 493 7514
Contact: Nasir Ahmed, MD 914 493 7514

United States, New York
Westchester Medical Center/New York Medical College Recruiting
Valhalla, New York, United States, 10595
Contact: Karen Seiter, MD    914-493-7514   
Principal Investigator: Karen Seiter, MD         
Sub-Investigator: Delong Liu, MD, PhD         
Sub-Investigator: Claudio Sandoval, MD         
Sponsors and Collaborators
New York Medical College
Principal Investigator: Karen Seiter, MD New York Medical College
  More Information

Responsible Party: Karen Seiter, Professor of Medicine, New York Medical College Identifier: NCT01513603     History of Changes
Other Study ID Numbers: L-10,442 
Study First Received: January 11, 2012
Last Updated: January 19, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Epstein-Barr Virus Infections
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Burkitt Lymphoma
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on October 27, 2016